Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis

Learn how the experts incorporate KIT-targeted therapies into management of patients with advanced systemic mastocytosis in this multidisciplinary panel discussion featuring Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky.
Prithviraj Bose, MD
person default
Ilene A. Galinsky, NP
Caitlin R. Rausch, PharmD
Released: March 10, 2022

In this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapies into management of patients with advanced systemic mastocytosis. Topics include:

  • Diagnosis and prognosis of advanced systemic mastocytosis
  • Clinical trial data on efficacy of avapritinib and midostaurin
  • Monitoring for and managing key toxicities with avapritinib, including cognitive dysfunction

Information on this Educational Activity

Faculty

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has received funds for research support from Astellas, Blueprint, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior and consulting fees from AbbVie, Blueprint, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology.
Caitlin R. Rausch, PharmD

Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, has no relevant conflicts of interest to report.
Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts

Ilene A. Galinsky, NP, has disclosed that she has received consulting fees from AbbVie, Jazz, Novartis, and Pfizer.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Blueprint Medicines

Related Content

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 17, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Results from retrospective Pre-MEASURE study evaluating the prognostic value of NGS-MRD testing in patients with AML in first remission prior to allogeneic HCT, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings